UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934

For the month of September 2023

Commission File Number: 001-37643

PURPLE BIOTECH LTD. (Translation of registrant's name into English)

4 Oppenheimer Street, Science Park, Rehovot 7670104, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Purple Biotech Ltd. (the "Company" or the "Registrant") is announcing that it has made available an updated Company Presentation on its website. A copy of the updated Company Presentation is attached hereto as Exhibit 99.1 and may be viewed at the Company's website at www.purple-biotech.com.

Exhibit

99.1 Purple Biotech Corporate Presentation September 2023

Incorporation by Reference

This Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 20, 2016 (Registration file number 333-211478), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538), the Registrant's Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on July 16, 2018 (Registration file number 333-226195), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327), the Registrant's Registration Statement on Form F-1 filed with the Securities and Exchange Commission on December 27, 2019 (Registration file number 333-235729), the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration file number 333- 238229), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on May 18, 2020 (Registration file number 333-238481), each of the Registrant's Registration Statements on Form F-3 filed with the Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant's Registration Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the Registrant's Registration Statement on Form F-3 filed with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769) and the Registrant's Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission on December 8, 2022 (Registration file number 333-268710), to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

September 13, 2023 PURPLE BIOTECH LTD.

By: /s/ Lior Fhima

Lior Fhima Chief Financial Officer

Forward-looking Statements and Safe Harbor

Certain statements in this press release that are forward-looking statements within the nearing of the sate harlor provisions of the Private Securites Lligation Reform Act of 1995. Such forward-looking statements that are not limited to, statements of historical fact, and may be llentified by words such a "believ"," expect" "intend", "plan", "may", "shuld", "night", "see", "will", "project", "toritiopat" or their negatives or wristions of thee words or the comparable words or the comparable word that these statements do not relates. You should not place under eliance on these forward-looking satements, which are not guarantees of future performance. Ioneard-looking statements reflect our current views, expect to future events, and are subject to a number of assumptions, include inoun and unionewn risk, may of which are beend our control, as well as uncertaintes and the factor that specificantly different for activements to be signitiation of actives of actives on activernents expressed or implied by the forward-coling statements. Inportant to such differences include, anong others, risk relating to the expected benfits, synergies and costs of the transction, management plans election the octential fruge fransal imped of the transction and any assumptions any of the creasing the expected ining of the cranaction and the parties' allin to complete the tansactives of management for future operations; product development for NT229 and 0M24 as well as Immunizati Ltd. sportfolio of inestigational tri-specific antibody compounts to be aring sage therapeutic candidates could potentially ed to an approved trup, product is loga and subject to highly significant isks, particularly with respect to act that drug development and commercialization invives a lengthy and expersive protes with unertial outcome; our ablily to successfuly develop and commecialize ou pharmateuts of any divical trais; the impact of any changes in regulation and legistion that could affect the pharmaceutcal hously in receing the regulatory approals neessary in orders, the difficulty of products of the U.S. Food and Inq-Admisistation or any the applicable regulator of pharmazeutial products and change in the heath policies and regimes in the countries in vicit we operating surrounding the accoal market reeption to our pharmacedial products one particular market; the introduction of competing product; patents datained by competitor; dependence on the ffectivens of our patents and other protections for informative products and defend issed patents; the commencement of any patent interference of infringener action agains our patents, and ou ability to previl, obtain a favor damages in any such action, and the exposure to litigation, and/or regulatory actions, and other factors that are discused in our Annual Report of For the year ended December 31, 2022 and in other filings with the U.S.C., including our cartionary discussion of risks and unerataines under "Risk Factors" in our Registation Statimate of that we believe cuse our actual results to differ naterially from expected results. Other factor beider hos we have lised could also adversely affect us. Any forward-looking in this press reless only as of the date with it is made. We discain any intertion or obligation to publicy use foward-looking statement or other information on the winter as a result of new inframation, future events or opticable law. You are advised, howeve, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, https://www.sec.gov.

Corporate Highlights

Purple Biotech identifies promising first-in-class drug candidates to treat cancers with high unmet medical need

· Multiple data read-outs expected in 2023 & 2024
· Two First-in-Class clinical stage drugs
· A preclinical tri-specific immuno-engagers platform
· Lean & global operation
· Cash runway into 1H25

Purple Biotech (NASDAQ/TASE: PPBT)

As of June 30, 2023

· ADS Outstanding: 21.4 M
Cash Balance : \$18 M

Leadership Team

Eric K. Rowinsky, MD Chairman of the Board Former CMO at ImClone, Stemline, Board member at Biogen Inc. Biogen ( ) Incorporated

Michael Schickler, PhD Head of Clinical and Regulatory Affairs Formerly at Hoffmann-La Roche, CEO at CureTech

(Roche)

Gil Efron Chief Executive Officer Former Deputy CEO & CFO at Kamada (NASDAQ:KMDA)

& KAMADA

Hadas Reuveni, PhD VP Research & Development Formerly at Keryx
(NASDAQ:KERX)

Lior Fhima Chief Financial Officer Formerly at Kamada (NASDAQ:KMDA)

Fabien Sebille, PhD Chief Business Officer Formerly at Debiopharm Debiopharm

A Pipeline Dedicated to Advancing Oncology Therapies

And State of Addition Commenses of the

Development Stage Value Drivers Project Target Indications Pre-Clinical | Phase I | Phase II | Phase III | Phase III * Phase 2 interim analysis 2H23 & CEACAM1 Pancreatic Cancer CM24* 1H24 mAb (+nivolumab+SoC) ✈ Phase 2 top line results 2H24 Solid tumors (monotherapy) + Phase 1 results STAT3xIRS1/2 2H23 NT219 Head and Neck Dual Inhibitor & Phase 2 1H24 Colorectal Cancer (+Cetuximab) CD 3x 5T 4xNKG2A IM1240 Solid Tumors Tri-specific Ab * Clinical collaboration and supply agreement with: {|| Bristol Myers Squilbb" Multiple data read-outs expected in the next 12 months

Advancing First-in-Class Oncology Therapies

CM24: an a-CEACAM1* mAb

Lead indication: Pancreatic Ductal Adenocarcinoma (PDAC)

*Carcinoembryonic Antigen Cell Adhesion Molecule

	7 CM24: a New Multi - Functional Immune Checkpoint Inhibitor • CEACAM1 is overexpressed on certain tumor cells and infiltrating immune cells • CEACAM1 interacts with CEACAM1 and CEACAM5 and creates a tumor - protective environment Attractive new target • CM24 increases T cell and NK cells cytotoxicity against tumors • CM24 shows benefit in combination with immuno - oncology treatments • CM24 blocks adhesion of tumor cells to Neutrophil Extra cellular Traps (NETs) Demonstrated mechanism of action • Favorable safety profile in monotherapy and in combination with nivolumab* • Partial response and stable disease in dose escalation study with nivolumab • Potential biomarkers identified such as NETs and CEACAM1 levels on TILs • Randomized Phase 2 initiated in Q1 2023 Signals of clinical efficacy • Significant unmet medical need in pancreatic ductal adenocarcinoma (PDAC), most common form of pancreatic cancer • Strong IP position and well ahead of competitors • Multiple opportunities to leverage the MoA in other clinical settings Sizable market potential

CM24 MOA | Immune Check Point Inhibitor & Anti-Metastatic Activity

Morki d 1, Menus 102, 2005, Innuncion 2002, Cancel mand Imments 2012, Inc., McConce, 10, 2002, Hong. 2002, Mary, 2012, Mary, 2012, Mary, 2012, 2012, Ports, 2012, 2012, Ports

CEACAM1 is Over-Expressed in Pancreatic Cancer

Comparison between CEACAM1 staining intensity in pancreatic cancer (38 cases/76 cores) and normal (10 cases/20 cores) tissues

Representative examples of CEACAM1 immunohistochemical images of pancreatic adenocarcinoma and normal tissues

Large Market Opportunity in Pancreatic Cancer

• Pancreatic Cancer accounts for ~60K new cases/year in the US alone; with a 5-year relative survival rate of 11.5%²

Immuno-oncology approaches have been limited to patients with high microsatellite instablity (MS-H) or high tumor mutational burden (TMB-H)
· 5-year overall survival rate with chemotherapy in 2nd line patients is 3%1
· 3 L standard of care regimens efficacy data: patients treapy: Overall Survival (OS) 2 morths, OS of 3-4 months with chemotherapy
· 2L standard of care regimens efficacy data: Gencitaxel : OS 7.9 months, Progression Free Survival (PFS) 4.3 months or Nal-lRl/5FU/LV: OS 6.2 months, PFS 3.1 months
· CEACAM1 expression correlates with poor prognosis in Pancreatic cancer2
Preclinical data support significant synergy of CM24 with currently marketed immuno-oncology therapies

Combining nivolumab with CM24 in a clinical collaboration with Bristol Myers Squibb

(Ill Bristol Myers Squibb"

American Cancer Society, Cancer Facts & Figures 2019, and the ACS website, https://seer.cancer.gov/stotlact.shtml/pancreas.blzn I Filmerican Child Child Chicantion in the collection micros (CAAM) 5, 5 m 6 on binners (CACAM) 25, 2012) component and CORMACIA (CAST 12020).
I. DLINE, Canada MP, Claser V. im . Hubner R. Sivec . I. et ... MAPU 1 paye 3 study of lingtean in metatatic parcestic cance: Final peral survival and constructions of constructions of concernsions of conc 4. Wang

doi:10.1016/j.ejca.2018.12.007

CM24 Phase 1 Dose Escalation Results Encouraging data in 2L/3L Pancreatic Ductal Adenocarcinoma (PDAC) patients

Study Results

14 patients were evaluable for efficacy:

Best overall response included 1 Partial . Response (PR) (PDAC) and 4 Stable Disease (SD) (3 PDAC and 1 papillary thyroid cancer (PTC))
· Pharmacokinetic analysis of CM24 shows exposure is dose-proportional across the 3 doses in this study
· Well tolerated with no Dose Limiting Toxicities (DLTs) and no grade ≥ 4 Adverse Events (AEs)
· Median Overall Survival 4.5 months (95% Cl 2.0-11.1) for 11 PDAC patients

Advancing First-in-Class Oncology Therapies

NT219: A Small Molecule Dual Inhibitor of IRS 1/2 and STAT3

Lead indication: Recurrent/Metastatic Head & Neck Cancer (SCCHN)

NT219 - A Novel Approach to Overcome Resistance to EGFRi and Beyond

NT219 blocks 2 critical signalling pathways at once

IRS1/2

· Scaffold proteins, mediating mitogenic, metastatic, angiogenic and antiapoptotic signals from IGF1R, IR, IL4R and other oncogenes, overexpressed in multiple tumors
· Regulates major survival pathways such as the PI3K/AKT, MEK/ERK and WNT/βcatenin
· Activated as a feedback response to anti-cancer therapies
IRS plays an important role in promoting a tumor-protective microenvironment, by mediating upregulation of TAMs and CAFs

Anti-apoptotic signal netastasis, EMT and immune evasio

STAT3

· Well-established transcription factor associated with the tumorigenic phenotype
· STAT3 is broadly hyperactivated in many cancers, promoting proliferation, survival, angiogenesis and metastasis
· STAT3 pathway is required for TGFBinduced EMT and cancer cell migration and invasion
· STAT3 is a critical player in tumor immune evasion, suppressing immune stimulators and enhancing immunosuppressive factors

cs 200, 73, upd 2 656f, liade Rever i et 1. Mor Rever it al. Mo Career Ter. 2012 (12) 2017) 13:47 (10) 2010) 12:40 (1) 10) 10.
html (1) 10 (10) 2014 44. Trend Plannot St. 201

NT219 Restores Sensitivity to EGFRi in PDX Models

Lung Cancer

Non-small cell lung cancer (NSCLC) Exon 19 deletion EGFR and T790M, biopsy of bone marrow metastasis, patient previously progressed on afatinib and osimertinib

Head & Neck Cancer

Recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) metastasis, patient progressed on chemoradiation, several chemotherapies and pembrolizumab

Osimertinib 5 mg/kg, NT219 65 mg/kg, mean tumor volume at the end point, 3 mice/group;

Treatments on days 0, 3 and 10, cetuximab - 1mg/mouse, 3 mice/group; PBMCs (1.4M cells/mouse) were injected on day 6 ** p<0.01, * p<0.02 based on one-way ANOVA with post hoc Tukey's HSD test

First Market Opportunity

Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Targeting the unmet medical need

SCCHN is the 6th most common cancer type ; 175k new cases/year are expected by 2024
1L standard of care has shifted from chemotherapy towards immuno-oncology + chemotherapy
· < 20% of R/M SCCHN patients respond to Pembrolizumab
Market size forecasted to >\$5b in 2030

NT219 Phase 1 Dose Escalation Monotherapy Interim Results

Study Design

· As of data cutoff date of May 12th, 2022, a total of 14 patients were enrolled and 12 patients were evaluable for dose limiting toxicity (DLT) determination (4 colorectal cancer, 3 pancreatic cancer, 2 breast cancer, 1 GEJ, 1 esophageal, and 1 appendiceal cancer)
· Median number of prior treatment regimens for metastatic disease was 4 (2-11).

Safety

. No DLTs were observed across all dose levels.
- Nine Grade 3 adverse events (AEs) were observed, two of which possibly related to NT219

			Grade
AE Term	Total	1	2	3	4/5
Fatigue	6	6
Constipation	4	4
ALP increased	3	2		1
ALT increased	3	1	2
Anemia	3	1	2
AST increased	3	1	1	1
Diarrhea	3	2	1
Headache	3	3
Nausea	3	2	1
Abdominal pain	2	1	1
Belching	2	2
Cough	2	2
Dizziness	2	2
Dyspnea	2	2
Edema limbs	2	2
Fever	2	2
Hot flashes	2	2
Hyperhidrosis	2	2
Urinary tract infection	2		2
Closed displaced fracture of right
femoral neck	1			1
Intractable right hip pain	1			1
Malignant hypercalcemia	1			1
Toxic Encephalopathy	1			1
Worsening back pain	1			1
Abdominopelvic Ascites	1			1

NT219 Phase 1 Dose Escalation Monotherapy Interim Results: Encouraging Initial Efficacy Signals

· For the 12 evaluable patients, best overall response included one confirmed Partial Response (gastroesophageal junction (GEJ) patient, > 5.5 months duration of response following end of treatment), and 3 Stable Disease with one patient awaiting follow up MRI/CT scans
· As of the cutoff date (May 12th , 2022), 10/12 patients are either on treatment or in follow up (range 1.1 to 18 months).

JRPLE

Durable Partial Response in a GEJ patient and Stable Disease in 3 out of 4 mutated KRAS colorectal cancer patients

NT219 Monotherapy and Combination Phase 1/2 Study Design (NCT04474470)

Study Title

A Phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion to assess the safety, tolerability, PK, PD and efficacy of NT219, alone in adults with recurrent or metastatic solid tumors and in combination with Erbitux® (cetuximab) in Head and Neck cancer

Endpoints

Primary end points:

Secondary end points:

maximum tolerated dose (MTD)

Obtain preliminary efficacy data

Safety, pharmacokinetics and to determine the

Advancing First-in-Class Oncology Therapies

IM1240: CD3x5T4xNKG2A Conditionally-Activated Tri-Specific Antibody

A Novel Mechanism of Action Tri-Specific Antibody

· Multi-specific biologics is an expanding class of drugs getting a lot of interest in the industry
· After initial success in hemato-oncology, new formats are being investigated in solid tumors
· Technology displays several distinctive features:
- · Dual engagement of T cells and NK cells to mount an optimal anti-tumoral immune response
- · A tumor-restricted activation through a cleavable capping system designed to provide a wide therapeutic index
- · Carefully selected Tumor Associated Antigens allowing patient-centric development

5T4, a Novel Target in Oncology 5T4 is highly expressed on certain tumors and correlates with poor prognosis Am J Cancer Res 2018;8(4):610 - 623 www.ajcr.us /ISSN:2156 - 6976/ajcr0074519 5T4 is a Tumor Associated Antigen prevalent to several large indications Opportunity of patient stratification strategy (5T4 + ) | 24

Promising Proof of Concept Data

• Sustained regressions in Breast Cancer xenograft model (MDA-MB-231) · The Pro-Tribody Capped-CD3x5T4xNKG2A performed better than the

uncapped variant .

No change in body weight